Putting a POC Troponin to the Test - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Putting a POC Troponin to the Test

Independent verification shows strong precision and concordance with lab assays across clinical thresholds.

  • By

  • Julie Greenbaum

  • February 5, 2026

  • 3 min

Share

Objective:

To verify the analytical performance and concordance of the QuidelOrtho TriageTrue point-of-care high-sensitivity troponin I assay in patients assessed for myocardial infarction.

Approach:
    Key Findings:
    • Intra-assay precision CVs were 25% and 12.2% at mean concentrations of 2.4 ng/L and 8.5 ng/L, respectively, with overall performance metrics indicating adequacy.
    • Hemolysis caused minimal interference up to 10 g/L, exceeding the manufacturer's claim.
    • Correlation coefficients with other assays ranged from 0.89 to 0.99, except for Roche hs-TnT assay (0.79).
    • All 116 comparisons with secondary analyzers met acceptable limits.
    Interpretation:

    The hs-TnI assay on the TriageTrue demonstrates adequate performance for clinical use, supporting its integration into clinical pathways based on the findings.

    Limitations:
    • Logistical constraints in obtaining suitable whole blood EDTA samples limited targeted sampling at specific troponin I levels, impacting the study's findings.
    Conclusion:

    The assay's analytical performance supports its use in emergency care and low-resource settings, aligning with manufacturer claims and emphasizing its clinical significance.

    Sources:

Original Source(s)

Putting a POC Troponin to the Test

  • by Julie Greenbaum

  • February 5, 2026

Related Content

FDA Flags Missing Trial Results

Federal outreach seeks to improve compliance with ClinicalTrials.gov reporting requirements and make more complete clinical trial information publicly available

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

Alternative Isoforms May Refine Variant Interpretation

Long-read transcript sequencing uncovered protein-altering variants missed by reference transcript analyses and identified functional effects for a lung-specific DPP9 isoform.